Intern - Sustainability (October 2024 Onwards)

**Education required**:Bachelor Degree in Digital/Business Marketing or Mass Communications

**Other requirements**:Must be enrolled at a University for the duration of your Internship

**Language requirement**:Written and spoken fluency in English

**Expected Start Date**:October 2024 onwards

**Looking to gain valuable real world work experience and help **positively impact the health of billions of people**?**

A GSK internship offers you the opportunity to kickstart your career - to take on a real role with genuine impact You’ll take on challenging, serious work on live projects or assignments. You’ll also get to learn from us, develop your skills and gain valuable experience for wherever the future takes you.

With an investment of S$510 million, our state-of-the-art vaccines manufacturing facility at Tuas was opened in June 2009 by Singapore's Prime Minister Lee Hsien Loong, coinciding with our 50th anniversary in Singapore. Comprising two production buildings, an administration block, quality control laboratories, utility plant and warehousing, the facility became operational in 2011. The facility and operations meet the high quality and good manufacturing standards of global regulatory bodies such as the European Medicines Agency and the United States Food and Drug Administration.

Tuas is a key manufacturing site within our network supplying the active ingredient used to make our pneumococcal conjugate vaccine. This paediatric vaccine is indicated for the active immunisation against pneumonia, invasive diseases and acute otitis media caused by _Streptococcus pneumoniae_ in infants and children.

Tuas site also focuses on manufacturing Hib (_Haemophilus influenzae_ type b_) antigen which is used in the manufacture of several paediatric vaccines. Hib is a bacterium responsible for invasive diseases, such as severe pneumonia and meningitis, contracted almost exclusively by children less than five years old.

These two vaccine products manufactured at Tuas cover a number of diseases causing paediatric mortality in the world, making a significant contribution to our global health agenda. The site continues to invest in developing technical capability and process improvement, and embracing new technology such as digital, data and analytics to position itself as a centre of excellence for the manufacture of vaccines.

**Watch GSK Tuas Introduction video**

**Why GSK?**

**Uniting science, technology and talent to get ahead of disease together.**

GSK is a global biopharma company with a special purpose - to unite science, technology and talent to get ahead of disease together - so we can positively impact the health of billions of people and deliver stronger, more sustainable shareholder returns - as an organisation where people can thrive. We prevent and treat disease with vaccines, specialty and general medicines. We focus on the science of the immune system and the use of new platform and data technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/ immunology and oncology).

Our success absolutely depends on our people. While getting ahead of disease together is about our ambition for patients and shareholders, it’s also about making GSK a place where people can thrive. We want GSK to be a place where people feel inspired, encouraged and challenged to be the best they can be. A place where they can be themselves - feeling welcome, valued, and included. Where they can keep growing and look after their wellbeing. So, if you share our ambition, join us at this exciting moment in our journey to get Ahead Together.

**Important notice to Employment businesses/ Agencies